Differential response of MDA‑MB‑231 breast cancer and MCF10A normal breast cells to cytoskeletal disruption

Kwon,Sangwoo; Han,Se Jik; Kim,Kyung Sook

doi:10.3892/or.2023.8637

Differential response of MDA‑MB‑231 breast cancer and MCF10A normal breast cells to cytoskeletal disruption

Authors:
- Sangwoo Kwon
- Se Jik Han
- Kyung Sook Kim
View Affiliations

Affiliations: Department of Biomedical Engineering, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
Published online on: September 29, 2023 https://doi.org/10.3892/or.2023.8637
Article Number: 200
Copyright: © Kwon et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis remains a major clinical problem in cancer diagnosis and treatment. Metastasis is the leading cause of cancer‑related mortality but is still poorly understood. Cytoskeletal proteins are considered potential therapeutic targets for metastatic cancer cells because the cytoskeleton serves a key role in the migration and invasion of these cells. Vimentin and F‑actin exhibit several functional similarities and undergo quantitative and structural changes during carcinogenesis. The present study investigated the effects of vimentin and F‑actin deficiency on the survival and motility of breast cancer cells. In metastatic breast cancer cells (MDA‑MB‑231) and breast epithelial cells (MCF10A), vimentin was knocked down by small interfering RNA and F‑actin was depolymerized by latrunculin A, respectively. The effect of reduced vimentin and F‑actin content on cell viability was analyzed using the MTT assay and the proliferative capacity was compared by analyzing the recovery rate. The effect on motility was analyzed based on two processes: The distance traveled by tracking the cell nucleus and the movement of the protrusions. The effects on cell elasticity were measured using atomic force microscopy. Separately reducing vimentin or F‑actin did not effectively inhibit the growth and motility of MDA‑MB‑231 cells; however, when both vimentin and F‑actin were simultaneously deficient, MDA‑MB‑231 cells growth and migration were severely impaired. Vimentin deficiency in MDA‑MB‑231 cells was compensated by an increase in F‑actin polymerization, but no complementary action of vimentin on the decrease in F‑actin was observed. In MCF10A cells, no complementary interaction was observed for both vimentin and F‑actin.

View Figures

View References

1	Lin Z, Han Y, Wu B and Fang W: Altered cytoskeletal structures in transformed cells exhibiting obviously metastatic capabilities. Cell Res. 1:141–51. 1990. View Article : Google Scholar
2	Fletcher DA and Mullins RD: Cell mechanics and the cytoskeleton. Nature. 463:485–492. 2010. View Article : Google Scholar : PubMed/NCBI
3	Yamaguchi H and Condeelis J: Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta. 1773:642–652. 2007. View Article : Google Scholar : PubMed/NCBI
4	Tang DD and Gerlach BD: The roles and regulation of the actin cytoskeleton, intermediate filaments and microtubules in smooth muscle cell migration. Respir Res. 18:542017. View Article : Google Scholar : PubMed/NCBI
5	Liu CY, Lin HH, Tang MJ and Wang YK: Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget. 6:15966–15983. 2015. View Article : Google Scholar : PubMed/NCBI
6	Sun B, Fang Y, Li Z, Chen Z and Xiang J: Role of cellular cytoskeleton in epithelial-mesenchymal transition process during cancer progression. Biomed Rep. 3:603–610. 2015. View Article : Google Scholar : PubMed/NCBI
7	Battaglia RA, Delic S, Herrmann H and Snider NT: Vimentin on the move: New developments in cell migration. F1000Res. 7:17962018. View Article : Google Scholar
8	Wu S, Du Y, Beckford J and Alachkar H: Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia. J Transl Med. 16:1702108. View Article : Google Scholar
9	Tadokoro A, Kanaji N, Liu D, Yokomise H, Haba R, Ishii T, Takagi T, Watanabe N, Kita N, Kadowaki N and Bandoh S: Vimentin regulates invasiveness and is a poor prognostic marker in non-small cell lung cancer. Anticancer Res. 36:1545–1551. 2106.PubMed/NCBI
10	Kwon S, Yang W, Moon D and Kim KS: Comparison of cancer cell elasticity by cell type. J Cancer. 11:5403–5412. 2020. View Article : Google Scholar : PubMed/NCBI
11	Li X, Kierfeld J and Lipowsky R: Actin polymerization and depolymerization coupled to cooperative hydrolysis. Phys Rev Lett. 103:0481022009. View Article : Google Scholar : PubMed/NCBI
12	Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
13	Peng GE, Wilson SR and Weiner OD: A pharmacological cocktail for arresting actin dynamics in living cells. Mol Biol Cell. 22:3986–3994. 2011. View Article : Google Scholar : PubMed/NCBI
14	Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, Zeng J, Nascimento PRBB, Sequeira VB, Butler TL, et al: A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Res. 73:5169–5182. 2013. View Article : Google Scholar : PubMed/NCBI
15	Tang K, Xin Y, Li K, Chen X and Tan Y: Cell cytoskeleton and stiffness are mechanical indicators of organotropism in breast cancer. Biology (Basel). 10:2592021.PubMed/NCBI
16	Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, Petruželka L, Kumar S, Sanz-Moreno V and Brábek J: Migrastatics-anti-metastatic and anti-invasion drugs: Promises and challenges. Trends Cancer. 3:391–406. 2017. View Article : Google Scholar : PubMed/NCBI
17	Fife CM, McCarroll JA and Kavallaris M: Movers and shakers: Cell cytoskeleton in cancer metastasis. Brit J Pharmacol. 171:5507–5523. 2014. View Article : Google Scholar : PubMed/NCBI
18	Atteeq M: Evaluating anticancer properties of withaferin A-a potent phytochemical. Front Pharmacol. 13:9753202022. View Article : Google Scholar : PubMed/NCBI
19	Nagy Z, Cheung BB, Tsang W, Tan O, Herath M, Ciampa OC, Shadma F, Carter DR and Marshall GM: Withaferin A activates TRIM16 for its anti-cancer activity in melanoma. Sci Rep. 10:197242020. View Article : Google Scholar : PubMed/NCBI
20	Burikhanov R, Sviripa VM, Hebbar N, Zhang W, Layton WJ, Hamza A, Zhan CG, Watt DS, Liu C and Rangnekar VM: Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nat Chem Biol. 10:924–926. 2014. View Article : Google Scholar : PubMed/NCBI
21	Cheratta AR, Thayyullathil F, Pallichankandy S, Subburayan K, Alakkal A and Galadari S: Prostate apoptosis response-4 and tumor suppression: It's not just about apoptosis anymore. Cell Death Dis. 12:472021. View Article : Google Scholar : PubMed/NCBI
22	Giganti A and Friederich E: The actin cytoskeleton as a therapeutic target: State of the art and future directions. Prog Cell Cycle Res. 5:511–525. 2003.PubMed/NCBI
23	Cramer LP: Role of actin-filament disassembly in lamellipodium protrusion in motile cells revealed using the drug jasplakinolide. Curr Biol. 9:1095–1105. 1999. View Article : Google Scholar : PubMed/NCBI
24	Strouhalova K, Přechová M, Gandalovičová A, Brábek J, Gregor M and Rosel D: Vimentin intermediate filaments as potential target for cancer treatment. Cancers (Basel). 12:1842020. View Article : Google Scholar : PubMed/NCBI
25	Han R and Chen J: A modified Sneddon model for the contact between conical indenters and spherical samples. J Mater Res. 36:1762–1771. 2021. View Article : Google Scholar
26	Hou S, Isaji T, Hang Q, Im S, Fukada T and Gu J: Distinct effects of integrin β₁ on cell proliferation and cellular signaling in MDA-MB-231 breast cancer cells. Sci Rep. 6:184302016. View Article : Google Scholar : PubMed/NCBI
27	Vinckier A and Semenza G: Measuring elasticity of biological materials by atomic force microscopy. FEBS Lett. 430:12–16. 1998. View Article : Google Scholar : PubMed/NCBI
28	Ridley AJ: Life at the leading edge. Cell. 145:1012–1022. 2011. View Article : Google Scholar : PubMed/NCBI
29	Gagliardi PA, Puliafito A, Blasio L, Chianale F, Somale D, Seano G, Bussolino F and Primo L: Real-time monitoring of cell protrusion dynamics by impedance responses. Sci Rep. 5:102062015. View Article : Google Scholar : PubMed/NCBI
30	Wilson K, Lewalle A, Fritzsche M, Thorogate R, Duke T and Charras G: Mechanisms of leading-edge protrusion in interstitial migration. Nat Commun. 4:28962013. View Article : Google Scholar : PubMed/NCBI
31	Duarte S, Viedma-Poyatos Á, Navarro-Carrasco E, Martínez AE, Pajares MA and Pérez-Sala D: Vimentin filaments interact with the actin cortex in mitosis allowing normal cell division. Nat Commun. 10:42002019. View Article : Google Scholar : PubMed/NCBI
32	Mezu-Ndubuisi OJ and Maheshwari A: The role of integrins in inflammation and angiogenesis. Pediatr Res. 89:1619–1626. 2021. View Article : Google Scholar : PubMed/NCBI
33	Alberts B, Johnson A, Lewis J, Raff M, Roberts K and Walter P: Molecular biology of the cell. 4th edition. New York: Garland Science; 2002
34	Luo M and Guan JL: Focal adhesion kinase: A prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett. 289:127–139. 2010. View Article : Google Scholar : PubMed/NCBI
35	Gemperle J, Dibus M, Koudelková L, Rosel D and Brábek J: The interaction of p130Cas with PKN3 promotes malignant growth. Mol Oncol. 13:264–289. 2019. View Article : Google Scholar : PubMed/NCBI
36	Madan R, Smolkin MB, Cocker R, Fayyad R and Oktay MH: Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma. Hum Pathol. 37:9–15. 2006. View Article : Google Scholar : PubMed/NCBI
37	Guan JL and Shalloway D: Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature. 358:690–692. 1992. View Article : Google Scholar : PubMed/NCBI
38	Guan JL: Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer. IUBMB Life. 62:268–276. 2010.PubMed/NCBI
39	Hahm ER, Mathan SV, Singh RP and Singh SV: Breast cancer selective disruption of actin cytoskeleton by diallyl trisulfide. J Cancer Prev. 27:101–111. 2022. View Article : Google Scholar : PubMed/NCBI
40	Meng Z, Li Z, Xie M, Yu H, Jiang L and Yao X: TM9SF4 is an F-actin disassembly factor that promotes tumor progression and metastasis. Nat Commun. 13:57282022. View Article : Google Scholar : PubMed/NCBI
41	Mierke CT: Mechanical cues affect migration and invasion of cells from three different directions. Front Cell Dev Biol. 8:5832262020. View Article : Google Scholar : PubMed/NCBI
42	Jonietz E: Mechanics: The forces of cancer. Nature. 491:S56–S57. 2012. View Article : Google Scholar : PubMed/NCBI
43	Alibert C, Goud B and Manneville JB: Are cancer cells really softer than normal cells? Biol Cell. 109:167–189. 2017. View Article : Google Scholar : PubMed/NCBI
44	Xu W, Mezencev R, Kim B, Wang L, McDonald J and Sulchek T: Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. PLoS One. 7:e466092012. View Article : Google Scholar : PubMed/NCBI
45	Kim TH, Gill NK, Nyberg KD, Nguyen AV, Hohlbauch SV, Geisse NA, Nowell CJ, Sloan EK and Rowat AC: Cancer cells become less deformable and more invasive with activation of β-adrenergic signaling. J Cell Sci. 129:4563–4575. 2016.PubMed/NCBI
46	Sahai E: Illuminating the metastatic process. Nat Rev Cancer. 7:737–749. 2007. View Article : Google Scholar : PubMed/NCBI
47	Pachmayr E, Treese C and Stein U: Underlying mechanisms for distant metastasis-molecular biology. Visc Med. 33:11–20. 2017. View Article : Google Scholar : PubMed/NCBI